We found that circNfix could attenuate Ang II–induced cardiac hypertrophy in vitro and TAC-induced cardiac hypertrophy in vivo by regulating the miR-145-5p/activating transcription factor 3 (ATF3) axis. The gene discussed is ATF3; the disease is cardiac hypertrophy.